Table 5.
Clinical events committee event rates (%) at 30 days
| All patients | With reclassification* | |||||
| Event | Eptifibatide | Placebo | P | Eptifibatide | Placebo | P |
| Death or myocardial infarction | ||||||
| Eastern Europe | 21.0 | 19.7 | 18.0 | 17.9 | ||
| Latin America | 16.1 | 15.7 | 14.1 | 13.2 | ||
| North America | 11.7 | 15.0 | 11.7 | 15.0 | ||
| Western Europe | 13.8 | 14.8 | 12.9 | 13.7 | ||
| Overall | 14.2 | 15.7 | 0.042 | 13.3 | 14.9 | 0.021 |
| Myocardial infarction | ||||||
| Eastern Europe | 18.8 | 17.3 | 15.8 | 15.3 | ||
| Latin America | 11.6 | 11.7 | 9.6 | 9.1 | ||
| North America | 10.1 | 12.9 | 10.1 | 12.9 | ||
| Western Europe | 12.6 | 12.9 | 11.7 | 11.8 | ||
| Overall | 12.6 | 13.6 | 0.137 | 11.6 | 12.7 | 0.08 |
*See Methods; 98 patients with low clinical certainty reclassified as having no infarction.